The tobramycin peak level examination is employed to evaluate therapeutic effectiveness. This broad-spectrum aminoglycoside is utilized for aerobic gram-negative bacteria resistant to less-toxic antibiotics, as well as for definitive or empirical treatment of Acinetobacter, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Providencia stuartii, and Serratia. Healthcare providers utilize this test to tailor the dose per administration to achieve optimal therapeutic effectiveness.